Citi Pharma, Martin Dow to Make New Biotech Product With Top Chinese Company

Citi Pharma Limited, Martin Dow, and Kingbo Pharmatec (a leading China-based pharmaceutical company) have entered into a Memorandum of Understanding (MOU) to collaborate on the development and manufacturing of a new biotech/biologic product. This partnership is aimed at reducing Pakistan’s reliance on imported medicines by enabling the local production of this essential product for both domestic use and export. To achieve this, the three companies will jointly establish a state-of-the-art manufacturing facility in Indonesia. Strategically located to meet the needs of both the Pakistani market and international customers, this facility will adhere to the highest global quality standards. This collaboration is not only set to enhance Pakistan’s pharmaceutical capabilities but will also contribute significantly to the growth of the global pharmaceutical industry. Kingbo Pharmatec will play a pivotal role in the technical aspects of this partnership, overseeing the establishment of the manufacturing plant and ensuring that all production processes align with global quality and regulatory standards. In collaboration with Citi Pharma and Martin Dow, Kingbo will also help unlock new export opportunities, expanding the product’s reach across international markets. This initiative aligns with Citi Pharma’s Vision 2030, which aims to introduce advanced biologics and biotechnology products to Pakistan. The objective is to make these critical products more affordable and accessible to the people of Pakistan while simultaneously generating export revenues that can significantly contribute to the national economy. By producing the product locally, this venture will reduce healthcare costs, save foreign exchange spent on imports, and strengthen Pakistan’s position in the global pharmaceutical market. Beyond its economic impact, this collaboration also represents a commitment to improving global public health. The three companies are dedicated to ensuring the availability of high-quality, affordable medicines for Pakistan and beyond, ultimately contributing to disease prevention and enhancing healthcare outcomes. The partnership is expected to drive a positive economic impact by reducing medicine costs, conserving foreign exchange, and opening new revenue streams through exports. The combined efforts of Citi Pharma, Martin Dow, and Kingbo Pharmatec are set to play a key role in Pakistan’s pharmaceutical growth and economic development. As this collaboration progresses, further updates on key milestones and achievements will be shared.